NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, utilizes a ...

Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. How to Spot the Market Bottom: Matt Maley has navigated ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

Seventy-one University of Kentucky students will present their research at the National Conference on Undergraduate Research (NCUR), April 7-9 at Duquesne University in Pittsburgh.